Pharmaceutical water is the most tightly regulated utility in drug manufacturing. The water grade your process requires \u2014 and the system that produces it \u2014 is not a purchasing decision; it’s a regulatory one. Getting it wrong means failed batch testing, 483 observations, and potential production shutdown. Getting it right means a validated, documented water system that satisfies both USP and FDA expectations for the life of the facility.<\/p>\n
This guide covers what each pharmaceutical water grade requires, which systems produce them, how to specify a compliant system, and what a pharma-grade RO installation actually costs.<\/p>\n
USP <1231> (Water for Pharmaceutical Purposes) defines the water quality standards used in drug manufacturing in the United States. The grades, in ascending order of purity:<\/p>\n
SWFI is WFI that has been sterilized and packaged. Additional grades include Sterile Purified Water, Bacteriostatic Water for Injection, and Water for Hemodialysis \u2014 each with specific USP monographs. These are finished products, not production water grades.<\/p>\n
RO is the core purification step for Purified Water systems. A properly designed pharmaceutical RO system removes 95\u201399.5% of TDS, eliminates bacteria and endotoxins from the feed water, and reduces conductivity to 2\u20135 \u00b5S\/cm. This is not sufficient alone for USP Purified Water conductivity requirements \u2014 a polishing step is needed.<\/p>\n
Double-pass RO (two RO stages in series) can achieve conductivity of 0.5\u20131 \u00b5S\/cm at the permeate outlet, which may meet USP PW limits in some conditions, but pharmaceutical facilities standardly follow RO with EDI rather than relying on double-pass RO alone.<\/p>\n
EDI uses ion exchange resin beds continuously regenerated by an applied electric field. It produces ultrapure water at 0.05\u20130.1 \u00b5S\/cm (18 megohm-cm) without chemical regeneration. Placed downstream of RO, EDI is the standard polishing step for pharmaceutical Purified Water systems. The combination \u2014 RO + EDI \u2014 produces water that comfortably meets USP PW conductivity requirements with a validated, chemical-free continuous process.<\/p>\n
Multi-effect distillation (MED) or vapor compression distillation is the FDA-required production method for WFI in the US. Distillation removes all non-volatile impurities and produces pyrogen-free water. Capital cost is higher than membrane systems, and energy consumption is significant (2\u20135 kWh per cubic meter), but it is the only path to USP WFI compliance in a US pharmaceutical facility.<\/p>\n
UV at 185 nm (TOC reduction) and 254 nm (microbial) is used at two points in pharmaceutical water systems: upstream of EDI for TOC reduction (to protect the EDI resin), and in the distribution loop for continuous bioburden control. UV is not a primary purification step \u2014 it does not remove dissolved solids or reduce conductivity.<\/p>\n
A typical pharmaceutical Purified Water system is a multi-stage treatment train, not a single piece of equipment. Standard design for a US facility using municipal feed water:<\/p>\n
A pharmaceutical water system is not just equipment \u2014 it’s a validated utility that must comply with FDA’s Current Good Manufacturing Practice (cGMP) regulations (21 CFR Parts 210\/211). Key compliance elements:<\/p>\n